Browse > Article
http://dx.doi.org/10.17946/JRST.2015.38.4.17

Comprehensive Clinical Study of Concurrent Chemotherapy Breathing IMRT Middle Part of Locally Advanced Esophageal Cancer  

Jung, Jae Hong (Dept. of Radiation Oncology, College of Medicine, Soonchunhyang University of Korea)
Kim, Seung-Chul (Dept. of Radiology, Songho College of Korea)
Moon, Seong-Kwon (Dept. of Radiation Oncology, College of Medicine, Soonchunhyang University of Korea)
Publication Information
Journal of radiological science and technology / v.38, no.4, 2015 , pp. 463-475 More about this Journal
Abstract
The standard treatment of locally advanced type of mid-esophageal cancer is concurrent chemoradiation therapy (CRT). We evaluated the feasibility of chemotherapy with adding docetaxel to the classical basic regimens of cisplatin plus 5-fluorouracil (5-FU) and radiotherapy up to 70.2 Gy using dose escalations for esophageal cancer. It was possible to escalate radiation treatment dose up to 70.2 Gy by the respiratory-gated intensity-modulated radiotherapy (gated-IMRT) based on the 4DCT-simulation, with improving target coverage and normal tissue (ex., lung, heart, and spinal cord) sparing. This study suggested that the definitive chemo-radiotherapy with docetaxel, cisplatin, and 5-fluorouracil (i.e., DCF-R) and gating IMRT is tolerable and active in patients with locally advanced mid-esophageal cancer (AEC).
Keywords
Docetaxel; Gating IMRT; 4DCT-simulation; Esophageal cancer;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ulmer W, Pyyry J, Kaissi W: 3D photon superposition/ convolution algorithm and its foundation on results of Monte Carlo calculations, Phys Med Biol, 50(8), 1767-1790, 2005   DOI
2 Geh JI, Bond SJ, Bentzen SM, Glymme-Jones R: Systematic overview of preoperative (neoadjuvant) chemo-radiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response, Radiother Oncol, 78(3), 236-234, 2006   DOI
3 Webb S, Nahum AE: A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density, Phys Med Biol, 38(6), 653-666, 1993   DOI
4 Gagliardi G, Constine LS, Moiseenko V, et al: Radiation dose-volume effects in the heart, Int J Radiat Oncol Biol Phys, 76, S77-85, 2010   DOI
5 Lyman JT: Complication probability as assessed from dose-volume histograms, Radiat Res Suppl, 8, S13-19, 1985   DOI
6 Kutcher GJ, Burman C: Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method, Int J Radiat Oncol Biol Phys, 16(6), 1623-1630, 1989   DOI
7 Keall PJ, Mageras GS, Balter JM et al.: The management of respiratory motion in radiation oncology report of AAPM Task Group 76, Med Phys, 33(10), 3874-3900, 2006   DOI
8 Cohen RJ, Paskalev K, Litwin S, Price RA Jr, Feigenberg SJ, Konski AA: Esophageal motion during radiotherapy: quantification and margin implications, Dis Esophagus, 23(6), 473-479, 2010   DOI
9 Gao XS, Qiaol X, Cao L et al.: Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma, Int J Radiat Oncol Biol Phys, 67(2), 389-396, 2007   DOI
10 Welsh J, Palmer MB, Aiani JA et al.: Esophageal cancer dose escalation using a simultaneous integrated boost technique, Int J Radiat Oncol Biol Phys, 82(1), 468-474, 2012   DOI
11 International Commission on Radiation Units and Measurements. ICRU report 62. Prescribing, recording and reporting photon beam therapy. Supplement to ICRU report 50 1999 Bethesda, MD: ICRU
12 Keal P, Vedam SV, George R et al.: The clinical implementation of respiratory-gated intensitymodulated radiotherapy, Med Dosim, 31(2), 152-162, 2006   DOI
13 Wallis JW, Lerner TR, Lerner CA: Three-dimensional display in nuclear medicine, Med Imag IEEE Trans, 8(2), 297-330, 1989   DOI
14 Wolf MC, Stahl M, Krause BJ et al.: Curative treatment of esophageal carcinoma: Current options and future developments, Radiat Oncol, 6(1), 55, 2011   DOI
15 Teoh AY, Chiu PW, Yeung WK et al.: Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: Results from a randomized controlled trial, Ann Oncol, 24(1), 165-171, 2012   DOI
16 Cunningham D, Starling N, Ashley S: Capecitabine and oxaliplatin for advanced esophagogastric cancer, N Engl J Med, 362(9), 858-859, 2010   DOI
17 Button MR, Morgan CA, Croydon ES, Roberts SA, Crosby TD: Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemo-radiotherapy, Int J Radiat Oncol Biol Phys, 73(3), 818-823, 2009   DOI
18 Minsky BD, Pajak TF, Ginsberg RJ et al.: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy, J Clin Oncol, 20(5), 1167-1174, 2002   DOI
19 Zhang Z, Liao Z, Jin J et al.: Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy, Int J Radiat Oncol Biol Phys, 61(3), 656-664, 2005   DOI
20 Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R: Systematic overview of preoperative (neoadjuvant) chemo-radiotherapy trials in oesophageal cancer: Evidence of a radiation and chemotherapy dose response, Radiother Oncol, 78(3), 236-244, 2005   DOI
21 Gwynne S, Falk S, Gollins S et al.: Oesophageal chemo-radiotherapy in the UK: current practice and future directions, Clin Oncol (R Coll Radiol), 25(6), 368-377, 2013   DOI
22 Martel MK, Sahijdak WM, Ten Haken RK, Kessler ML, Turrisi AT: Fraction size and dose parameters related to the incidence of pericardial effusions, Int J Radiat Oncol Biol Phys, 40(1), 155-161, 1998   DOI
23 Hatakenaka M, Yonezawa M, Honda H: Acute cardiac impairment associated with concurrent chemo- radiotherapy for esophageal cancer: Magnetic resonance evaluation, Int J Radiat Oncol Biol Phys, 83(1), e67-e73, 2012   DOI
24 Bedenne L, Michel P, Bouche O et al.: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102, J Clin Oncol, 25(10), 1160-1168, 2007   DOI
25 Higuchi K, Koisumi W, Hayakawa K: A phase I trial of definitive chemo-radiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501), Radiother Oncol, 87(3), 398-404, 2008   DOI
26 Ishida K, Ando N, Yamamoto S, Ide H, Shioda M: Phase II study of cisplatin and 5 fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: A Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516), Jpn J Clin Oncol, 34(10), 615-619, 2004   DOI
27 Ilson DH, Ajani J, Bhalla K et al.: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus, J Clin Oncol, 16(5), 1826-1834, 1998   DOI
28 Dunne AL, Mothersill C, Robson T, Wilson GD, Hirst DG: Radiosensitization of colon cancer cell lines by docetaxel: Mechanisms of action, Oncol Res, 14(9), 447-454, 2004   DOI
29 Donahue JM, Nichols FC, S chomas DA et al.: Complete pathologic response after neoadjuvant chemo-radiotherapy for esophageal cancer is associated with enhanced survival, Ann Thorac Surg, 87(2), 398-398, 2009
30 Siegel R, Naishadham D, Jemal A: Cancer statistics 2012, Cancer J Clin, 62(1), 10-29, 2012   DOI
31 Orringer MB, Marshall B, Iannettoni MD: Transhiatal esophagectomy: clinical experience and refinements, Ann Surg, 230(3), 392-400, 1999   DOI
32 Chang AC, Ji H, Birkmeyer NJ, Orringer MB, Birkmeyer JD: Outcomes after transhiatal and transthoracic esophagectomy for cancer, Ann Thorac Surg, 85(2), 424-429, 2008   DOI
33 Prins MJ, Ruurda JP, van Diest PJ, van Hillegersberg R, Ten Kate FJ: The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study, Ann Oncol, 24(5), 1290-1297, 2013   DOI
34 Suzuki A, Xiao L, Hayashi Y et al.: Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemo-radiotherapy, Cancer, 117(21), 4823-4833, 2011   DOI
35 Gillies RS, Middleston MR, Han C et al.: Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma, Br J Surg, 99(2), 239-245, 2012   DOI